Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease

doi:10.4254/wjh.v7.i25.2610

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 25

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9161)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

501

WORD

282

HTML

3352

Tables (1-5)

236

Sum=4371

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

505

Download

944

Sum=1449

Publishing Process of This Article

Item

Count

Browse

1116

Download

2225

Sum=3341

Nov 8, 2015 (publication date) through Jan 14, 2025

Times Cited of This Article

Times Cited (22)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Hepatol. Nov 8, 2015; 7(25): 2610-2618
Published online Nov 8, 2015. doi: 10.4254/wjh.v7.i25.2610

Table 1 Characteristics of patients with nonalcoholic fatty liver disease, divided according to nonalcoholic fatty liver disease without type 2 diabetes mellitus and nonalcoholic fatty liver disease with type 2 diabetes mellitus (mean ± SD)

Parameter	All patients (n = 235)	NAFLD (without T2DM) (n = 158)	NAFLD (with T2DM) (n = 77)	P value
Age (yr)	45.3 ± 11.9	43.0 ± 12.2	49.9 ± 9.8	< 0.01
Gender (male/female)	91/144	69/89	22/55	0.02
Race (% Caucasian)	65.1	63.9	67.5	0.9
BMI (kg/m²)	37.6 ± 11.5	35.9 ± 10.6	41.0 ± 12.6	< 0.01
Hypertension, n (%)	114 (48.1)	59 (37.3)	55 (71.4)	< 0.01
Dyslipidemia, n (%)	139 (68.8)	82 (61.2)	57 (83.8)	< 0.01
Metabolic syndrome, n (%)	115 (53.7)	52 (36.4)	63 (88.7)	< 0.01
Abnormal LFT’s as an indication of liver biopsy, n (%)	159 (67.6)	117 (74.0)	42 (54.5)	0.02
Platelets	257.5 ± 73.5	262.6 ± 67.7	247.4 ± 83.3	0.15
INR	0.99 ± 0.16	0.97 ± 0.10	1.02 ± 0.23	0.03
Protein (g/dL)	7.4 ± 0.72	7.4 ± 0.73	7.3 ± 0.70	0.12
Albumin (g/dL)	4.3 ± 0.5	4.3 ± 0.5	4.2 ± 0.46	0.06
AST (U/L)	49.8 ± 34.5	50.4 ± 38.4	48.3 ± 24.8	0.6
ALT (U/L)	72.6 ± 58.5	79.2 ± 65.4	59.2 ± 38	0.01
Bilirubin (mg/dL)	0.67 ± 0.4	0.68 ± 0.4	0.62 ± 0.3	0.3
Alkaline Phosphate	96.7 ± 61.8	94.9 ± 68.2	100.1 ± 46.9	0.5
Total cholesterol (mg/dL)	200.2 ± 47.3	200.9 ± 45.4	198.8 ± 50.9	0.8
HDL cholesterol (mg/dL)	44.3 ± 11.8	44.2 ± 12.0	44.6 ± 11.7	0.9
Triglycerides (mg/dL)	211.4 ± 119.9	209.7 ± 127.7	214.4 ± 105.9	0.8
LDL cholesterol (mg/dL)	118.9 ± 41.0	120.5 ± 41.3	116.4 ± 40.8	0.6
Fasting glucose (mg/dL)	125.6 ± 55.5	102.9 ± 28.3	167.0 ± 67.8	< 0.01
HbA1c	6.93 ± 2.09	5.83 ± 1.11	8.09 ± 2.26	< 0.01
Iron (μg/dL)	82.6 ± 38.7	89.3 ± 40.8	71.3 ± 32.0	< 0.01
Total iron binding capacity (μg/dL)	322.4 ± 72.3	317.16 ± 71.8	333.0 ± 72.9	0.2
Ferritin (ng/mL)	258.2 ± 306.0	281 ± 323.1	223.0 ± 276.7	0.3
AST/ALT	0.836 ± 0.432	0.781 ± 0.434	0.947 ± 0.41	< 0.01
FIB-4 index	1.26 ± 1.01	1.06 ± 0.77	1.65 ± 1.28	< 0.01
APRI	0.581 ± 0.471	0.549 ± 0.458	0.643 ± 0.493	0.16

NAFLD: Nonalcoholic fatty liver disease; T2DM: Type 2 diabetes mellitus; AST: Aspartate transaminase; ALT: Alanine transaminase; LDL: Low-density lipoprotein cholesterol; NAS: NAFLD activity score; HDL: High-density lipoprotein cholesterol; BMI: Body mass index; INR: International normalized ratio; APRI: AST to platelet ratio index; LFT: Liver function test.

Table 2 Characteristics of patients with nonalcoholic fatty liver disease, divided according to nonalcoholic steatohepatitis and steatosis (mean + SD)

Parameter	All patients (n = 235)	NASH	Steatosis	P value
Age (yr)	45.3 + 11.9	45.9 + 12.4	43.8 + 10.4	0.2
Gender (male/female)	91/144	67/101	24/43	0.6
Race (% caucasian)	65.1	64.9	65.7	0.1
BMI (kg/m²)	37.7 + 11.5	37 + 10.6	39.4 + 13.7	0.17
Hypertension, n (%)	114 (48.5)	82 + 48.8	32 + 63.9	1
Dyslipidemia, n (%)	139 (68.8)	100 (70.9)	39 (63.9)	0.3
Metabolic syndrome, n (%)	115 + 53.7	67 (42.7)	32 (56.1)	0.08
Platelets	258 + 73.5	247 + 72.1	283 + 71.1	< 0.01
INR	0.996 + 0.162	1 + 0.178	0.98 + 0.112	0.3
Protein (g/dL)	7.39 + 0.762	7.39 + 0.733	7.37 + 0.714	0.8
Albumin (g/dL)	4.27 + 0.536	4.27 + 0.555	4.26 + 0.487	0.8
AST (U/L)	49.8 + 34.5	54.2 + 36.3	38.3 + 26.1	< 0.01
ALT (U/L)	72.6 + 58.5	78.7 + 63.1	57 + 40.7	0.01
Bilirubin (mg/dL)	0.668 + 0.416	0.71 + 0.456	0.567 + 0.275	0.01
Alkaline Phosphate	96.7 + 61.8	100 + 70.9	88.3 + 28.3	0.1
Total cholesterol (mg/dL)	200 + 47.3	202 + 48.6	197 + 44.5	0.5
HDL cholesterol (mg/dL)	44.4 + 11.9	42.7 + 10.7	48.1 + 13.6	0.01
Triglycerides (mg/dL)	211 + 120	220 + 125	191 + 105	0.18
LDL cholesterol (mg/dL)	1119 + 41	121 + 41.6	114 + 39.8	0.33
Fasting glucose (mg/dL)	126 + 55.5	129 + 55.9	117 + 53.8	0.14
HbA1c	6.93 + 2.09	7.12 + 2.19	6.37 + 1.69	0.11
Iron (μg/dL)	82.6 + 38.7	83.8 + 40.5	78.6 + 31.9	0.52
Total iron binding capacity (μg/dL)	322 + 72.3	319 + 74.6	335 + 63.4	0.31
Ferritin (ng/mL)	258 + 306	276 + 324	201 + 232	0.21
Mallory bodies	50 + 21.3	50 + 29.8	0	< 0.01
CAD	67 + 28.9	50 + 29.9	17 + 26.2	0.63
Gastric bypass	21 + 8.94	14 + 8.33	7 + 10.4	0.61
Cirrhosis	14 + 5.96	14 + 8.33	0	0.01
Steatosis	1.92 + 0.861	2.1 + 0.83	1.46 + 0.765	< 0.01
Inflammation	0.44 + 0.62	0.625 + 0.663	0	< 0.01
Fibrosis	0.753 + 1.11	1.05 + 1.21	0	< 0.01
Ballooning	0.821 + 0.712	1.15 + 0.575	0	< 0.01
NAS score	3.18 + 1.69	3.86 + 1.45	1.46 + 0.765	< 0.01

AST: Aspartate transaminase; ALT: Alanine transaminase; HDL: High-density lipoprotein cholesterol; NAS: Nonalcoholic fatty liver disease activity score; NASH: Nonalcoholic steatohepatitis; LDL: Low-density lipoprotein cholesterol; BMI: Body mass index; INR: International normalized ratio; CAD: Coronary artery disease.

Table 3 Histological findings of patients with nonalcoholic fatty liver disease, divided according to nonalcoholic fatty liver disease without type 2 diabetes mellitus and nonalcoholic fatty liver disease with type 2 diabetes mellitus n (%)

Parameter	All patients (n = 235)	NAFLD (without T2DM) (n = 158)	NAFLD (with T2DM) (n = 77)	P value
NAS score (mean ± SD)	3.2 ± 1.7	3.0 ± 1.6	3.5 ± 1.7	0.03
Fibrosis score (mean ± SD)	0.75 ± 1.1	0.52 ± 0.9	1.2 ± 1.3	< 0.01
Fibrosis score				< 0.01
< 2	191 (81.3)	139 (88.0)	52 (67.5)
≥ 2	44 (18.7)	19 (12.0)	25 (32.5)
NAS score				0.12
< 5	179 (76.2)	125 (79.1)	54 (70.1)
≥ 5	56 (23.8)	33 (20.9)	23 (29.9)
NAS score				0.11
< 3	90 (38.3)	66 (41.7)	24 (31.2)
≥ 3	145 (61.7)	92 (58.3)	53 (68.8)
Steatosis				0.1
< 2	97 (41.3)	71 (44.9)	26 (33.8)
≥ 2	138 (58.7)	87 (55.1)	51 (66.2)
Ballooning				< 0.01
< 2	193 (82.1)	137 (86.7)	56 (72.7)
2	42 (17.9)	21 (13.3)	21 (27.3)
Inflammation				0.4
< 2	218 (92.7)	148 (93.7)	70 (90.9)
≥ 2	17 (7.3)	10 (6.3)	7 (9.1)
Mallory bodies	50 (21.3)	28 (17.7)	22 (28.6)	0.06

NAFLD: Nonalcoholic fatty liver disease; NAS: NAFLD activity score; T2DM: Type 2 diabetes mellitus.

Table 4 Variables associated with nonalcoholic steatohepatitis (nonalcoholic fatty liver disease activity score ≥ 5) (multivariate analysis)

Variables	P value	Odds ratio	95%CI
All patients
Presence of T2DM	< 0.01	3.27	1.43-7.50
ALT ≥ 36	0.029	3.88	1.15-13.1
Protein	0.045	1.84	1.01-3.35
Patients with NAFLD without T2DM
Protein	0.048	3.06	1.01-9.25
Patients with NAFLD with T2DM
ALT ≥ 36	0.03	4.21	1.13-15.6

ALT: Alanine transaminase; NAFLD: Nonalcoholic fatty liver disease; T2DM: Type 2 diabetes mellitus.

Table 5 Variables associated with advanced fibrosis (multivariate analysis)

Variables	P value	Odds ratio	95%CI
All patients
Presence of T2DM	< 0.01	3.45	1.53-7.77
Platelet	0.025	0.99	0.99-1.0
INR	< 0.01	4151	97.7-176426
Patients with NAFLD without T2DM
Platelet	0.03	0.99	0.98-0.99
INR	0.001	16950	62.4-4607293
Patients with NAFLD with T2DM
Platelet	0.045	0.99	0.98-0.99

NAFLD: Nonalcoholic fatty liver disease; T2DM: Type 2 diabetes mellitus; INR: International normalized ratio.

Citation: Puchakayala BK, Verma S, Kanwar P, Hart J, Sanivarapu RR, Mohanty SR. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease. World J Hepatol 2015; 7(25): 2610-2618
URL: https://www.wjgnet.com/1948-5182/full/v7/i25/2610.htm
DOI: https://dx.doi.org/10.4254/wjh.v7.i25.2610